|
G |
ADIPOQ |
adiponectin, C1Q and collagen domain containing |
increases expression |
ISO |
Carnitine results in increased expression of ADIPOQ protein |
CTD |
PMID:30256492 |
|
NCBI chr 3:186,842,710...186,858,463
Ensembl chr 3:186,842,704...186,858,463
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:29186614 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
|
|
G |
APP |
amyloid beta precursor protein |
multiple interactions |
EXP |
Carnitine promotes the reaction [Paraquat deficiency inhibits the reaction [Paraquat promotes the reaction [APP protein binds to APP protein]]] |
CTD |
PMID:33290254 |
|
NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
decreases expression multiple interactions |
ISO |
Carnitine results in decreased expression of BAX protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in decreased expression of BAX protein]; Carnitine inhibits the reaction [Atrazine results in increased expression of BAX mRNA]; Carnitine inhibits the reaction [Methotrexate results in increased expression of BAX protein] |
CTD |
PMID:29186614 PMID:36282381 PMID:37312617 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BBOX1 |
gamma-butyrobetaine hydroxylase 1 |
multiple interactions increases chemical synthesis |
EXP |
Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Hydrogen Peroxide inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Ketoglutaric Acids inhibits the reaction [Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]]; Ketoglutaric Acids inhibits the reaction [Hydrogen Peroxide inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]] |
CTD |
PMID:21439360 |
|
NCBI chr11:27,040,815...27,127,809
Ensembl chr11:27,040,725...27,127,809
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions increases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of BCL2 protein]; Carnitine inhibits the reaction [Atrazine results in decreased expression of BCL2 mRNA]; Carnitine inhibits the reaction [Ifosfamide results in decreased expression of BCL2 mRNA]; Carnitine inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein] |
CTD |
PMID:23213347 PMID:29186614 PMID:36282381 PMID:37312617 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BCL2L1 |
BCL2 like 1 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Gentamicins results in decreased expression of BCL2L1 protein] |
CTD |
PMID:19491382 |
|
NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
ISO EXP |
Carnitine inhibits the reaction [Atrazine results in increased expression of CASP3 mRNA]; Carnitine inhibits the reaction [Gentamicins results in increased cleavage of CASP3 protein]; Carnitine inhibits the reaction [Ifosfamide results in increased expression of CASP3 mRNA]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of CASP3 mRNA]]; Carnitine inhibits the reaction [Methotrexate results in increased expression of CASP3 protein] Carnitine inhibits the reaction [quinone results in increased activity of CASP3 protein] |
CTD |
PMID:19491382 PMID:23213347 PMID:26562095 PMID:32478940 PMID:36282381 PMID:37312617 More...
|
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP8 |
caspase 8 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [quinone results in increased activity of CASP8 protein] |
CTD |
PMID:32478940 |
|
NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836
|
|
G |
CASP9 |
caspase 9 |
multiple interactions |
ISO EXP |
Carnitine inhibits the reaction [Ifosfamide results in increased expression of CASP9 mRNA] Carnitine inhibits the reaction [quinone results in increased activity of CASP9 protein] |
CTD |
PMID:23213347 PMID:32478940 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Diethylnitrosamine results in decreased activity of CAT protein]; Carnitine inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]; Carnitine inhibits the reaction [Ifosfamide results in decreased expression of CAT mRNA] |
CTD |
PMID:16889571 PMID:19294768 PMID:23213347 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCN2 |
cellular communication network factor 2 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Sunitinib results in increased expression of CCN2 mRNA] |
CTD |
PMID:26581635 |
|
NCBI chr 6:131,948,176...131,951,372
Ensembl chr 6:131,948,176...131,951,372
|
|
G |
CDH1 |
cadherin 1 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of CDH1 protein] |
CTD |
PMID:28973641 |
|
NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537
|
|
G |
COL1A1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of COL1A1 mRNA]; Carnitine inhibits the reaction [sunitinib results in increased expression of COL1A1 mRNA] |
CTD |
PMID:26581635 PMID:28973641 |
|
NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632
|
|
G |
COL2A1 |
collagen type II alpha 1 chain |
multiple interactions |
ISO |
[COL2A1 protein co-treated with Freund's Adjuvant] affects the abundance of Carnitine; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine] |
CTD |
PMID:24709313 |
|
NCBI chr12:47,972,967...48,006,212
Ensembl chr12:47,972,967...48,004,554
|
|
G |
CPT1A |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO EXP |
valproyl-coenzyme A inhibits the reaction [CPT1A protein results in increased metabolism of Carnitine] [Doxorubicin co-treated with Carnitine] results in increased expression of CPT1A mRNA; [Genistein co-treated with Carnitine] results in increased expression of CPT1A protein; Carnitine inhibits the reaction [quinone results in decreased expression of CPT1A protein] |
CTD |
PMID:16283381 PMID:16362726 PMID:19854160 PMID:32478940 |
|
NCBI chr11:68,754,620...68,844,277
Ensembl chr11:68,754,620...68,844,410
|
|
G |
CPT2 |
carnitine palmitoyltransferase 2 |
multiple interactions |
EXP |
Carnitine promotes the reaction [[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate] |
CTD |
PMID:21816645 |
|
NCBI chr 1:53,196,824...53,214,197
Ensembl chr 1:53,196,792...53,214,197
|
|
G |
CYBB |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Sunitinib results in increased expression of CYBB mRNA]; Carnitine inhibits the reaction [Sunitinib results in increased expression of CYBB protein] |
CTD |
PMID:26581635 |
|
NCBI chr X:37,780,059...37,813,461
Ensembl chr X:37,780,018...37,813,461
|
|
G |
CYP17A1 |
cytochrome P450 family 17 subfamily A member 1 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Atrazine results in decreased expression of CYP17A1 mRNA] |
CTD |
PMID:29710542 |
|
NCBI chr10:102,830,531...102,837,413
Ensembl chr10:102,830,531...102,837,472
|
|
G |
CYP2E1 |
cytochrome P450 family 2 subfamily E member 1 |
multiple interactions |
ISO |
Carnitine promotes the reaction [Ethanol results in increased expression of CYP2E1 protein] |
CTD |
PMID:8130774 |
|
NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220
|
|
G |
FABP3 |
fatty acid binding protein 3 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Doxorubicin results in decreased expression of FABP3 mRNA] |
CTD |
PMID:20470772 |
|
NCBI chr 1:31,359,588...31,373,076
Ensembl chr 1:31,365,253...31,376,850
|
|
G |
FABP9 |
fatty acid binding protein 9 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 protein] |
CTD |
PMID:33965443 |
|
NCBI chr 8:81,458,253...81,461,579
Ensembl chr 8:81,458,253...81,461,579
|
|
G |
FSHB |
follicle stimulating hormone subunit beta |
multiple interactions |
ISO |
Carnitine inhibits the reaction [carbendazim results in decreased expression of FSHB protein] |
CTD |
PMID:33965443 |
|
NCBI chr11:30,231,014...30,235,194
Ensembl chr11:30,231,014...30,235,261
|
|
G |
GFAP |
glial fibrillary acidic protein |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Atrazine results in increased expression of GFAP protein] |
CTD |
PMID:36282381 |
|
NCBI chr17:44,903,159...44,915,500
Ensembl chr17:44,903,159...44,916,937
|
|
G |
GPT |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Atrazine results in increased activity of GPT protein] |
CTD |
PMID:36282381 |
|
NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174
|
|
G |
GPX1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Ifosfamide results in decreased expression of GPX1 mRNA] |
CTD |
PMID:23213347 |
|
NCBI chr 3:49,357,176...49,358,353
Ensembl chr 3:49,357,174...49,358,605
|
|
G |
HADHA |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
multiple interactions |
EXP |
Carnitine inhibits the reaction [quinone results in decreased expression of HADHA protein] |
CTD |
PMID:32478940 |
|
NCBI chr 2:26,190,635...26,244,632
Ensembl chr 2:26,190,635...26,244,672
|
|
G |
HMOX1 |
heme oxygenase 1 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Methotrexate results in decreased expression of HMOX1 protein] |
CTD |
PMID:37312617 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
HRK |
harakiri, BCL2 interacting protein |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Gentamicins results in increased expression of HRK mRNA]; Carnitine inhibits the reaction [Gentamicins results in increased expression of HRK protein] |
CTD |
PMID:16239342 |
|
NCBI chr12:116,856,144...116,881,441
Ensembl chr12:116,856,144...116,881,441
|
|
G |
HSPA2 |
heat shock protein family A (Hsp70) member 2 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Cadmium Chloride results in increased expression of HSPA2 protein] |
CTD |
PMID:22359436 |
|
NCBI chr14:64,535,905...64,543,237
Ensembl chr14:64,535,905...64,546,173
|
|
G |
IDH2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Carnitine] |
CTD |
PMID:27469509 |
|
NCBI chr15:90,083,045...90,102,468
Ensembl chr15:90,083,045...90,102,477
|
|
G |
IL10 |
interleukin 10 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [carbendazim results in decreased expression of IL10 protein]; Carnitine inhibits the reaction [Sunitinib results in decreased expression of IL10 mRNA] |
CTD |
PMID:26581635 PMID:33965443 |
|
NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of IL1B mRNA]]; Carnitine inhibits the reaction [sunitinib results in increased expression of IL1B mRNA] |
CTD |
PMID:26562095 PMID:26581635 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [carbendazim results in increased expression of IL6 protein]; Carnitine inhibits the reaction [Methotrexate results in increased expression of IL6 protein]; Carnitine inhibits the reaction [Sunitinib results in increased expression of IL6 mRNA] |
CTD |
PMID:26581635 PMID:33965443 PMID:37312617 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
INS-IGF2 |
INS-IGF2 readthrough |
multiple interactions decreases uptake |
ISO |
Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased secretion of INS1 protein] INS1 protein results in decreased uptake of Carnitine |
CTD |
PMID:28298333 PMID:30256492 |
|
NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209
|
|
G |
LDHA |
lactate dehydrogenase A |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Doxorubicin results in increased activity of LDHA protein] |
CTD |
PMID:37453608 |
|
NCBI chr11:18,394,563...18,408,425
Ensembl chr11:18,394,560...18,408,425
|
|
G |
LEPR |
leptin receptor |
affects abundance |
ISO |
LEPR affects the abundance of Carnitine |
CTD |
PMID:20567778 |
|
NCBI chr 1:65,420,652...65,641,559
Ensembl chr 1:65,420,652...65,641,559
|
|
G |
LHB |
luteinizing hormone subunit beta |
multiple interactions |
ISO |
Carnitine inhibits the reaction [carbendazim results in decreased expression of LHB protein] |
CTD |
PMID:33965443 |
|
NCBI chr19:49,015,980...49,019,498
Ensembl chr19:49,015,980...49,017,091
|
|
G |
MMP9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [sunitinib results in decreased expression of MMP9 mRNA] |
CTD |
PMID:26581635 |
|
NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561
|
|
G |
MPO |
myeloperoxidase |
multiple interactions increases activity |
ISO |
[Carboplatin co-treated with Carnitine deficiency] results in increased expression of MPO protein; Acetaminophen promotes the reaction [Carnitine deficiency results in increased activity of MPO protein] |
CTD |
PMID:18597074 PMID:18852009 |
|
NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
|
|
G |
MT-CO1 |
mitochondrially encoded cytochrome c oxidase I |
multiple interactions |
ISO |
Carnitine inhibits the reaction [nickel chloride results in decreased expression of COX1 mRNA] |
CTD |
PMID:21419151 |
|
NCBI chr MT:5,904...7,445
Ensembl chr MT:5,904...7,445
|
|
G |
MT-ND6 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [nickel chloride results in decreased expression of ND6 mRNA] |
CTD |
PMID:21419151 |
|
NCBI chr MT:14,149...14,673
Ensembl chr MT:14,149...14,673
|
|
G |
MTTP |
microsomal triglyceride transfer protein |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Stavudine results in decreased expression of MTTP mRNA] |
CTD |
PMID:18299183 |
|
NCBI chr 4:99,564,130...99,623,997
Ensembl chr 4:99,564,081...99,623,997
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Methotrexate results in decreased expression of NFE2L2 protein] |
CTD |
PMID:37312617 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [carbendazim results in increased expression of NOS2 protein]; Carnitine inhibits the reaction [Ifosfamide results in increased expression of NOS2 mRNA] |
CTD |
PMID:23213347 PMID:33965443 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NOS3 |
nitric oxide synthase 3 |
increases expression |
ISO |
Carnitine results in increased expression of NOS3 |
CTD |
PMID:20123095 |
|
NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588
|
|
G |
OCLN |
occludin |
multiple interactions |
ISO |
Carnitine inhibits the reaction [carbendazim results in decreased expression of OCLN protein] |
CTD |
PMID:33965443 |
|
NCBI chr 5:69,492,547...69,558,104
Ensembl chr 5:69,492,292...69,558,104
|
|
G |
PPARA |
peroxisome proliferator activated receptor alpha |
multiple interactions increases activity |
ISO |
[pirinixic acid results in increased activity of PPARA protein] promotes the reaction [SLC22A21 protein results in increased uptake of Carnitine]; PPARA protein promotes the reaction [Carnitine results in decreased susceptibility to Gentamicins] Carnitine results in increased activity of PPARA protein |
CTD |
PMID:19491382 PMID:19735737 |
|
NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
multiple interactions increases expression |
ISO |
Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of PPARG protein] Carnitine results in increased expression of PPARG protein |
CTD |
PMID:30256492 |
|
NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356
|
|
G |
PPARGC1A |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Methotrexate results in decreased expression of PPARGC1A protein] |
CTD |
PMID:37312617 |
|
NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089
|
|
G |
PTGIS |
prostaglandin I2 synthase |
increases expression increases response to substance multiple interactions |
ISO |
Carnitine results in increased expression of PTGIS mRNA PTGIS protein results in increased susceptibility to Carnitine [Carnitine results in increased expression of PTGIS mRNA] which results in increased chemical synthesis of 6-Ketoprostaglandin F1 alpha |
CTD |
PMID:19491382 |
|
NCBI chr20:49,503,874...49,568,137
Ensembl chr20:49,503,874...49,568,137
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Carnitine inhibits the reaction [carbendazim results in increased expression of RELA protein] |
CTD |
PMID:33965443 |
|
NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090
|
|
G |
SIRT1 |
sirtuin 1 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Methotrexate results in decreased expression of SIRT1 protein] |
CTD |
PMID:37312617 |
|
NCBI chr10:67,884,656...67,918,390
Ensembl chr10:67,884,656...67,918,390
|
|
G |
SLC22A4 |
solute carrier family 22 member 4 |
increases uptake |
EXP |
SLC22A4 protein results in increased uptake of Carnitine |
CTD |
PMID:21256917 PMID:33007874 |
|
NCBI chr 5:132,294,394...132,344,190
Ensembl chr 5:132,294,394...132,344,190
|
|
G |
SLC22A5 |
solute carrier family 22 member 5 |
multiple interactions decreases expression increases transport increases uptake increases expression affects uptake affects binding |
EXP ISO |
[Doxorubicin co-treated with Carnitine] results in increased expression of SLC22A5 mRNA; Amiodarone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Atorvastatin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Betaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Carnitine inhibits the reaction [SLC22A5 protein results in increased abundance of Doxorubicin]; Carnitine inhibits the reaction [SLC22A5 protein results in increased transport of pivaloylcarnitine]; Choline inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Clozapine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; grepafloxacin affects the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Ipratropium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Lidocaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Nifedipine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Ofloxacin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Olanzapine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine analog]; pivaloylcarnitine inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]; Propranolol inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Quetiapine Fumarate inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Spironolactone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; talinolol inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; ziprasidone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] Carnitine inhibits the reaction [SLC22A5 protein results in increased abundance of and results in increased localization of Doxorubicin] Carnitine results in decreased expression of SLC22A5 mRNA; Carnitine results in decreased expression of SLC22A5 protein 1-Methyl-4-phenylpyridinium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 protein]; Carnitine inhibits the reaction [Doxorubicin results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [SLC22A5 protein results in increased uptake of Tetraethylammonium]; Dithioerythritol inhibits the reaction [Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]]; Ofloxacin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]; Tetraethylammonium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] Carnitine deficiency results in increased expression of SLC22A5 mRNA SLC22A5 protein results in increased uptake of Carnitine; SLC22A5 protein results in increased uptake of Carnitine analog SLC22A5 protein affects the uptake of Carnitine Carnitine binds to SLC22A5 protein |
CTD |
PMID:12644265 PMID:15486076 PMID:16283381 PMID:16928358 PMID:18762717 PMID:18981167 PMID:19041296 PMID:19539806 PMID:19735737 PMID:20303936 PMID:20470772 PMID:21256917 PMID:21641380 PMID:22701146 PMID:30465787 PMID:31437515 PMID:33007874 PMID:37453608 More...
|
|
NCBI chr 5:132,369,710...132,395,612
Ensembl chr 5:132,369,710...132,395,613
|
|
G |
SLC22A8 |
solute carrier family 22 member 8 |
increases transport |
ISO |
SLC22A8 protein results in increased transport of Carnitine |
CTD |
PMID:15100168 |
|
NCBI chr11:62,992,824...63,015,841
Ensembl chr11:62,989,154...63,015,841
|
|
G |
SLC25A20 |
solute carrier family 25 member 20 |
multiple interactions increases transport |
ISO |
Ampicillin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Carnitine inhibits the reaction [Hydrogen Peroxide results in decreased activity of SLC25A20 protein]; Cefazolin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Cefonicid inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Cephalothin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Piperacillin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine] |
CTD |
PMID:18452908 PMID:23402788 |
|
NCBI chr 3:48,856,926...48,898,882
Ensembl chr 3:48,856,926...48,898,904
|
|
G |
SLC2A4 |
solute carrier family 2 member 4 |
multiple interactions increases expression |
ISO |
Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of SLC2A4 protein] Carnitine results in increased expression of SLC2A4 protein |
CTD |
PMID:30256492 |
|
NCBI chr17:7,281,718...7,288,257
Ensembl chr17:7,281,718...7,288,257
|
|
G |
SNAI1 |
snail family transcriptional repressor 1 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of SNAI1 protein] |
CTD |
PMID:28973641 |
|
NCBI chr20:49,982,980...49,988,886
Ensembl chr20:49,982,980...49,988,886
|
|
G |
SREBF1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Stavudine results in increased expression of SREBF1 mRNA] |
CTD |
PMID:18299183 |
|
NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002
|
|
G |
STAR |
steroidogenic acute regulatory protein |
multiple interactions |
ISO |
Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR protein] |
CTD |
PMID:33965443 |
|
NCBI chr 8:38,142,700...38,150,952
Ensembl chr 8:38,142,700...38,150,992
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TGFB1 mRNA]]; Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of TGFB1 mRNA]; Carnitine inhibits the reaction [sunitinib results in increased expression of TGFB1 mRNA] |
CTD |
PMID:26562095 PMID:26581635 PMID:28973641 |
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
TIMP1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [sunitinib results in increased expression of TIMP1 mRNA] |
CTD |
PMID:26581635 |
|
NCBI chr X:47,582,436...47,586,789
Ensembl chr X:47,582,408...47,586,789
|
|
G |
TJP1 |
tight junction protein 1 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of TJP1 protein] |
CTD |
PMID:28973641 |
|
NCBI chr15:29,699,367...29,969,049
Ensembl chr15:29,699,367...29,968,915
|
|
G |
TNF |
tumor necrosis factor |
increases expression multiple interactions decreases expression |
ISO |
Carnitine deficiency results in increased expression of TNF mRNA [Carboplatin co-treated with Carnitine deficiency] results in increased expression of TNF protein; Acetaminophen promotes the reaction [Carnitine deficiency results in increased expression of TNF mRNA]; Carnitine inhibits the reaction [carbendazim results in increased expression of TNF protein]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TNF mRNA]]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TNF protein]]; Carnitine inhibits the reaction [Methotrexate results in increased expression of TNF protein] Carnitine results in decreased expression of TNF protein |
CTD |
PMID:18597074 PMID:18629605 PMID:18852009 PMID:26562095 PMID:33965443 PMID:37312617 More...
|
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
VIM |
vimentin |
multiple interactions |
ISO |
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of VIM protein] |
CTD |
PMID:28973641 |
|
NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593
|
|
|
G |
BBOX1 |
gamma-butyrobetaine hydroxylase 1 |
multiple interactions |
EXP |
[BBOX1 protein co-treated with Ketoglutaric Acids] results in increased metabolism of gamma-butyrobetaine |
CTD |
PMID:21439360 |
|
NCBI chr11:27,040,815...27,127,809
Ensembl chr11:27,040,725...27,127,809
|
|
G |
IDH2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of gamma-butyrobetaine] |
CTD |
PMID:27469509 |
|
NCBI chr15:90,083,045...90,102,468
Ensembl chr15:90,083,045...90,102,477
|
|
|
G |
A2M |
alpha-2-macroglobulin |
decreases expression |
EXP |
Aminocaproic Acid results in decreased expression of A2M protein |
CTD |
PMID:11304663 |
|
NCBI chr12:9,067,708...9,116,229
Ensembl chr12:9,067,664...9,116,229
|
|
G |
FOLH1 |
folate hydrolase 1 |
multiple interactions |
EXP |
[2-(3-(1,3-dicarboxypropyl)ureido)pentanedioic acid binds to Aminocaproic Acid binds to 1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononane binds to Valerates binds to bombesin (7-14) binds to Copper] inhibits the reaction [isospaglumic acid binds to FOLH1 protein] |
CTD |
PMID:24508213 |
|
NCBI chr11:49,145,092...49,208,602
Ensembl chr11:49,145,092...49,208,638
|
|
G |
GRPR |
gastrin releasing peptide receptor |
multiple interactions |
EXP |
[2-(3-(1,3-dicarboxypropyl)ureido)pentanedioic acid binds to Aminocaproic Acid binds to 1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononane binds to Valerates binds to bombesin (7-14) binds to Copper] inhibits the reaction [bombesin, Tyr(4)- binds to GRPR protein] |
CTD |
PMID:24508213 |
|
NCBI chr X:16,123,565...16,153,518
Ensembl chr X:16,123,565...16,153,518
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions |
ISO |
Aminocaproic Acid inhibits the reaction [PLG protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:17482686 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions |
ISO |
Aminocaproic Acid inhibits the reaction [PLG protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:17482686 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
PLG |
plasminogen |
multiple interactions |
ISO |
Aminocaproic Acid inhibits the reaction [PLG protein results in increased phosphorylation of MAPK1 protein]; Aminocaproic Acid inhibits the reaction [PLG protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:17482686 |
|
NCBI chr 6:160,702,193...160,754,097
Ensembl chr 6:160,702,194...160,754,097
|
|
G |
SERPINC1 |
serpin family C member 1 |
increases expression |
EXP |
Aminocaproic Acid results in increased expression of SERPINC1 protein |
CTD |
PMID:11304663 |
|
NCBI chr 1:173,903,800...173,917,327
Ensembl chr 1:173,903,800...173,917,327
|
|
|
G |
SLC22A5 |
solute carrier family 22 member 5 |
affects binding multiple interactions increases transport increases uptake |
EXP ISO |
pivaloylcarnitine binds to SLC22A5 protein Carnitine inhibits the reaction [SLC22A5 protein results in increased transport of pivaloylcarnitine]; pivaloylcarnitine inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine] SLC22A5 protein results in increased uptake of pivaloylcarnitine |
CTD |
PMID:18762717 PMID:19539806 |
|
NCBI chr 5:132,369,710...132,395,612
Ensembl chr 5:132,369,710...132,395,613
|
|
|
G |
ACACB |
acetyl-CoA carboxylase beta |
decreases expression |
ISO |
L-carnitine decreases expression of Acacb mRNA and protein in rat heart |
RGD |
PMID:30644033 |
RGD:329955369 |
NCBI chr12:109,111,189...109,268,226
Ensembl chr12:109,116,587...109,268,226
|
|
G |
CPT1A |
carnitine palmitoyltransferase 1A |
increases expression multiple interactions |
ISO |
L-carnitine increases expression of Cpt1a mRNA and protein in rat heart L-carnitine inhibits the reaction [sunitinib decreases expression of Cpt1a mRNA and protein in rat heart] |
RGD |
PMID:30644033 PMID:30644033 |
RGD:329955369, RGD:329955369 |
NCBI chr11:68,754,620...68,844,277
Ensembl chr11:68,754,620...68,844,410
|
|
G |
MLYCD |
malonyl-CoA decarboxylase |
increases expression multiple interactions |
ISO |
L-carnitine increases expression of Mlycd protein in rat heart L-carnitine inhibits the reaction [sunitinib increases expression of Mlycd protein in rat heart] |
RGD |
PMID:30644033 PMID:30644033 |
RGD:329955369, RGD:329955369 |
NCBI chr16:83,899,115...83,927,031
Ensembl chr16:83,899,115...83,951,445
|
|
G |
PRKAA2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
increases expression multiple interactions |
ISO |
L-carnitine increases expression of Ampka2 protein in rat serum and heart L-carnitine inhibits the reaction [sunitinib decreases expression of Ampka2 protein in rat serum and heart] |
RGD |
PMID:30644033 PMID:30644033 |
RGD:329955369, RGD:329955369 |
NCBI chr 1:56,645,314...56,715,335
Ensembl chr 1:56,645,314...56,715,335
|
|
|
G |
BIRC2 |
baculoviral IAP repeat containing 2 |
increases degradation |
EXP |
Lobaplatin increases degradation of BIRC2 protein in human nasopharyngeal carcinoma cells |
RGD |
PMID:32413426 |
RGD:155226873 |
NCBI chr11:102,347,214...102,378,670
Ensembl chr11:102,347,211...102,378,670
|
|
G |
BIRC3 |
baculoviral IAP repeat containing 3 |
increases degradation |
EXP |
Lobaplatin increases degradation of BIRC3 protein in human nasopharyngeal carcinoma cells |
RGD |
PMID:32413426 |
RGD:155226873 |
NCBI chr11:102,317,484...102,339,403
Ensembl chr11:102,317,484...102,339,403
|
|
|
G |
ACHE |
acetylcholinesterase (Yt blood group) |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [Dexamethasone results in decreased activity of ACHE protein]; Acetylcarnitine inhibits the reaction [Dexamethasone results in increased activity of ACHE protein] |
CTD |
PMID:21986892 |
|
NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974
|
|
G |
APEX1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
increases expression |
ISO |
Acetylcarnitine results in increased expression of APEX1 mRNA |
CTD |
PMID:14654561 |
|
NCBI chr14:20,455,226...20,457,767
Ensembl chr14:20,455,191...20,457,772
|
|
G |
ATP6V1F |
ATPase H+ transporting V1 subunit F |
increases expression |
ISO |
Acetylcarnitine results in increased expression of ATP6V1F mRNA |
CTD |
PMID:14654561 |
|
NCBI chr 7:128,862,856...128,865,847
Ensembl chr 7:128,862,856...128,865,847
|
|
G |
C1QA |
complement C1q A chain |
decreases expression |
ISO |
Acetylcarnitine results in decreased expression of C1QA mRNA |
CTD |
PMID:19555370 |
|
NCBI chr 1:22,636,463...22,639,678
Ensembl chr 1:22,635,077...22,639,678
|
|
G |
C4B |
complement C4B (Chido/Rodgers blood group) |
decreases expression |
ISO |
Acetylcarnitine results in decreased expression of C4B mRNA |
CTD |
PMID:19555370 |
|
NCBI chr 6:32,014,795...32,035,418
Ensembl chr 6:32,014,795...32,035,418
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [sodium arsenite results in increased activity of CASP3 protein]; Acetylcarnitine inhibits the reaction [Sodium Selenite results in increased expression of CASP3 mRNA] |
CTD |
PMID:20067779 PMID:29278859 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP9 |
caspase 9 |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [sodium arsenite results in increased activity of CASP9 protein] |
CTD |
PMID:29278859 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]; Acetylcarnitine inhibits the reaction [Sodium Selenite results in decreased expression of CAT mRNA] |
CTD |
PMID:20067779 PMID:26349760 PMID:29278859 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
COL2A1 |
collagen type II alpha 1 chain |
multiple interactions |
ISO |
[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Acetylcarnitine |
CTD |
PMID:24709313 |
|
NCBI chr12:47,972,967...48,006,212
Ensembl chr12:47,972,967...48,004,554
|
|
G |
CTSS |
cathepsin S |
decreases expression |
ISO |
Acetylcarnitine results in decreased expression of CTSS mRNA |
CTD |
PMID:19555370 |
|
NCBI chr 1:150,730,188...150,765,778
Ensembl chr 1:150,730,079...150,765,957
|
|
G |
CXCL14 |
C-X-C motif chemokine ligand 14 |
decreases expression |
ISO |
Acetylcarnitine results in decreased expression of CXCL14 mRNA |
CTD |
PMID:19555370 |
|
NCBI chr 5:135,570,679...135,578,991
Ensembl chr 5:135,570,679...135,579,279
|
|
G |
EGR1 |
early growth response 1 |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [Sodium Selenite results in increased expression of EGR1 mRNA] |
CTD |
PMID:20067779 |
|
NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303
|
|
G |
GFAP |
glial fibrillary acidic protein |
decreases expression |
ISO |
Acetylcarnitine results in decreased expression of GFAP mRNA |
CTD |
PMID:19555370 |
|
NCBI chr17:44,903,159...44,915,500
Ensembl chr17:44,903,159...44,916,937
|
|
G |
GSR |
glutathione-disulfide reductase |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [Acetaminophen results in decreased expression of GSR protein] |
CTD |
PMID:26265018 |
|
NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846
|
|
G |
GSTP1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
Acetylcarnitine affects the reaction [Dexamethasone results in decreased expression of GSTP1 mRNA] |
CTD |
PMID:21986892 |
|
NCBI chr11:67,583,812...67,586,653
Ensembl chr11:67,583,742...67,586,656
|
|
G |
HMOX1 |
heme oxygenase 1 |
multiple interactions |
ISO |
Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of HMOX1 mRNA] |
CTD |
PMID:21986892 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
HMOX2 |
heme oxygenase 2 |
multiple interactions |
ISO |
Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of HMOX2 mRNA] |
CTD |
PMID:21986892 |
|
NCBI chr16:4,474,736...4,510,347
Ensembl chr16:4,474,690...4,510,347
|
|
G |
HSPB1 |
heat shock protein family B (small) member 1 |
decreases expression |
ISO |
Acetylcarnitine results in decreased expression of HSPB1 mRNA |
CTD |
PMID:14654561 |
|
NCBI chr 7:76,302,673...76,304,292
Ensembl chr 7:76,302,673...76,304,295
|
|
G |
IDH2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Acetylcarnitine] |
CTD |
PMID:27469509 |
|
NCBI chr15:90,083,045...90,102,468
Ensembl chr15:90,083,045...90,102,477
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [sodium arsenite results in increased expression of IL1B protein] |
CTD |
PMID:29278859 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [sodium arsenite results in increased expression of IL6 protein] |
CTD |
PMID:29278859 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
MGST1 |
microsomal glutathione S-transferase 1 |
increases expression |
ISO |
Acetylcarnitine results in increased expression of MGST1 mRNA |
CTD |
PMID:14654561 |
|
NCBI chr12:16,347,115...16,593,331
Ensembl chr12:16,347,142...16,609,259
|
|
G |
MT-CO1 |
mitochondrially encoded cytochrome c oxidase I |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [Sodium Selenite results in decreased expression of COX1 mRNA] |
CTD |
PMID:20067779 |
|
NCBI chr MT:5,904...7,445
Ensembl chr MT:5,904...7,445
|
|
G |
NGF |
nerve growth factor |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [Cisplatin results in decreased expression of NGF protein] |
CTD |
PMID:14654561 |
|
NCBI chr 1:115,285,917...115,338,249
Ensembl chr 1:115,285,904...115,338,770
|
|
G |
NOS1 |
nitric oxide synthase 1 |
multiple interactions |
ISO |
Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of NOS1 mRNA] |
CTD |
PMID:21986892 |
|
NCBI chr12:117,208,142...117,361,626
Ensembl chr12:117,208,142...117,452,170
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of NOS2 mRNA] |
CTD |
PMID:21986892 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
PAH |
phenylalanine hydroxylase |
decreases expression |
ISO |
Acetylcarnitine results in decreased expression of PAH mRNA |
CTD |
PMID:19555370 |
|
NCBI chr12:102,836,889...102,958,441
Ensembl chr12:102,836,889...102,958,410
|
|
G |
PINK1 |
PTEN induced kinase 1 |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [Cadmium results in increased expression of PINK1] |
CTD |
PMID:25464205 |
|
NCBI chr 1:20,633,458...20,651,511
Ensembl chr 1:20,633,458...20,651,511
|
|
G |
PPARGC1A |
PPARG coactivator 1 alpha |
increases expression multiple interactions |
EXP |
Acetylcarnitine results in increased expression of PPARGC1A protein [Acetylcarnitine co-treated with Thioctic Acid] results in increased expression of PPARGC1A protein |
CTD |
PMID:20414966 |
|
NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089
|
|
G |
PRKN |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [Cadmium results in increased expression of PRKN] |
CTD |
PMID:25464205 |
|
NCBI chr 6:161,347,417...162,727,766
Ensembl chr 6:161,347,417...162,727,775
|
|
G |
PSMB6 |
proteasome 20S subunit beta 6 |
increases expression |
ISO |
Acetylcarnitine results in increased expression of PSMB6 mRNA |
CTD |
PMID:14654561 |
|
NCBI chr17:4,796,164...4,798,495
Ensembl chr17:4,796,144...4,798,502
|
|
G |
PTMA |
prothymosin alpha |
increases expression |
ISO |
Acetylcarnitine results in increased expression of PTMA mRNA |
CTD |
PMID:14654561 |
|
NCBI chr 2:231,708,525...231,713,551
Ensembl chr 2:231,706,895...231,713,551
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [sodium arsenite results in increased expression of RELA protein] |
CTD |
PMID:29278859 |
|
NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090
|
|
G |
RPS17 |
ribosomal protein S17 |
increases expression |
ISO |
Acetylcarnitine results in increased expression of RPS17 mRNA |
CTD |
PMID:14654561 |
|
NCBI chr15:82,536,750...82,540,457
Ensembl chr15:82,536,750...82,540,459
|
|
G |
SKAP2 |
src kinase associated phosphoprotein 2 |
decreases expression |
ISO |
Acetylcarnitine results in decreased expression of SKAP2 mRNA |
CTD |
PMID:19555370 |
|
NCBI chr 7:26,654,770...26,864,590
Ensembl chr 7:26,667,068...26,995,239
|
|
G |
SLC25A20 |
solute carrier family 25 member 20 |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [Hydrogen Peroxide results in decreased activity of SLC25A20 protein] |
CTD |
PMID:23402788 |
|
NCBI chr 3:48,856,926...48,898,882
Ensembl chr 3:48,856,926...48,898,904
|
|
G |
SNCA |
synuclein alpha |
multiple interactions |
EXP |
[Acetylcarnitine co-treated with Thioctic Acid] inhibits the reaction [Rotenone results in increased expression of SNCA protein]; Acetylcarnitine inhibits the reaction [Rotenone results in increased expression of SNCA protein] |
CTD |
PMID:20414966 |
|
NCBI chr 4:89,724,099...89,838,304
Ensembl chr 4:89,700,345...89,838,315
|
|
G |
TNNI3 |
troponin I3, cardiac type |
multiple interactions |
ISO |
Acetylcarnitine inhibits the reaction [Cisplatin results in increased expression of TNNI3 protein] |
CTD |
PMID:21034734 |
|
NCBI chr19:55,151,767...55,157,732
Ensembl chr19:55,151,767...55,157,773
|
|
|
G |
IDH2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of butyrylcarnitine] |
CTD |
PMID:27469509 |
|
NCBI chr15:90,083,045...90,102,468
Ensembl chr15:90,083,045...90,102,477
|
|
|
G |
CROT |
carnitine O-octanoyltransferase |
increases chemical synthesis |
ISO |
CROT protein results in increased chemical synthesis of octanoylcarnitine |
CTD |
PMID:6838215 |
|
NCBI chr 7:87,345,664...87,399,794
Ensembl chr 7:87,345,664...87,399,794
|
|
|
G |
COL2A1 |
collagen type II alpha 1 chain |
multiple interactions |
ISO |
[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Palmitoylcarnitine |
CTD |
PMID:24709313 |
|
NCBI chr12:47,972,967...48,006,212
Ensembl chr12:47,972,967...48,004,554
|
|
G |
GLS |
glutaminase |
increases chemical synthesis |
EXP |
GLS protein results in increased chemical synthesis of Palmitoylcarnitine |
CTD |
PMID:31040181 |
|
NCBI chr 2:190,880,821...190,965,552
Ensembl chr 2:190,880,821...190,965,552
|
|
G |
PPP3R1 |
protein phosphatase 3 regulatory subunit B, alpha |
decreases metabolic processing |
ISO |
PPP3R1 gene mutant form results in decreased metabolism of Palmitoylcarnitine |
CTD |
PMID:19700627 |
|
NCBI chr 2:68,178,857...68,252,532
Ensembl chr 2:68,178,857...68,256,237
|
|
G |
PRKAA1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
increases chemical synthesis |
EXP |
PRKAA1 protein results in increased chemical synthesis of Palmitoylcarnitine |
CTD |
PMID:31040181 |
|
NCBI chr 5:40,759,389...40,798,374
Ensembl chr 5:40,759,389...40,798,374
|
|
|
G |
ACOX1 |
acyl-CoA oxidase 1 |
increases metabolic processing multiple interactions |
ISO |
ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A [ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide; benz(a)anthracene promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]; Dehydroepiandrosterone promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]; Tetrachlorodibenzodioxin promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide] |
CTD |
PMID:10497882 |
|
NCBI chr17:75,941,507...75,979,166
Ensembl chr17:75,941,507...75,979,177
|
|
G |
CES1 |
carboxylesterase 1 |
increases hydrolysis |
ISO |
CES1 protein results in increased hydrolysis of Palmitoyl Coenzyme A |
CTD |
PMID:8611161 |
|
NCBI chr16:55,802,851...55,833,096
Ensembl chr16:55,802,851...55,833,337
|
|
G |
CPT1A |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
valproyl-coenzyme A inhibits the reaction [CPT1A protein results in increased metabolism of Palmitoyl Coenzyme A] |
CTD |
PMID:19854160 |
|
NCBI chr11:68,754,620...68,844,277
Ensembl chr11:68,754,620...68,844,410
|
|
G |
DGAT1 |
diacylglycerol O-acyltransferase 1 |
multiple interactions |
EXP |
DGAT1 protein results in increased metabolism of [Palmitoyl Coenzyme A co-treated with Vitamin A] |
CTD |
PMID:16214399 |
|
NCBI chr 8:144,314,584...144,326,852
Ensembl chr 8:144,314,584...144,326,910
|
|
G |
GSTA1 |
glutathione S-transferase alpha 1 |
multiple interactions |
EXP |
Palmitoyl Coenzyme A binds to and results in decreased activity of GSTA1 protein |
CTD |
PMID:10542059 |
|
NCBI chr 6:52,791,371...52,803,816
Ensembl chr 6:52,791,371...52,803,860
|
|
G |
HNF4A |
hepatocyte nuclear factor 4 alpha |
decreases expression |
EXP |
Palmitoyl Coenzyme A results in decreased expression of HNF4A mRNA; Palmitoyl Coenzyme A results in decreased expression of HNF4A protein |
CTD |
PMID:17992261 |
|
NCBI chr20:44,355,699...44,434,596
Ensembl chr20:44,355,699...44,432,845
|
|
G |
PPARA |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP ISO |
Palmitoyl Coenzyme A binds to and results in increased activity of PPARA protein Acetylglucosamine inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Atorvastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Atropine inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Budesonide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Enalapril inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Fenofibrate promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; gamma-Aminobutyric Acid inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; gedunin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]; Pravastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Pyrazinamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Saccharin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; salicylamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Tolazoline inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Tolmetin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]] |
CTD |
PMID:11139385 PMID:18812576 |
|
NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
multiple interactions |
EXP |
Palmitoyl Coenzyme A binds to and results in increased activity of PPARG protein |
CTD |
PMID:11139385 |
|
NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356
|
|
G |
SHBG |
sex hormone binding globulin |
decreases expression |
EXP |
Palmitoyl Coenzyme A results in decreased expression of SHBG mRNA; Palmitoyl Coenzyme A results in decreased expression of SHBG protein |
CTD |
PMID:17992261 |
|
NCBI chr17:7,614,064...7,633,372
Ensembl chr17:7,613,946...7,633,382
|
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
sodium propionate inhibits the reaction [Ethanol results in increased expression of BAX mRNA] |
CTD |
PMID:35639301 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
ISO |
sodium propionate inhibits the reaction [Ethanol results in increased expression of and results in increased cleavage of CASP3 mRNA] |
CTD |
PMID:35639301 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP8 |
caspase 8 |
multiple interactions |
ISO |
sodium propionate inhibits the reaction [Ethanol results in increased expression of CASP8 mRNA] |
CTD |
PMID:35639301 |
|
NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836
|
|
G |
CLDN1 |
claudin 1 |
multiple interactions |
ISO |
sodium propionate inhibits the reaction [Ethanol results in decreased expression of CLDN1 protein] |
CTD |
PMID:35639301 |
|
NCBI chr 3:190,305,707...190,322,446
Ensembl chr 3:190,305,707...190,322,446
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
multiple interactions |
ISO EXP |
sodium propionate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:31621310 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP1B1 |
cytochrome P450 family 1 subfamily B member 1 |
multiple interactions |
EXP |
sodium propionate promotes the reaction [biochanin A results in increased expression of CYP1B1 mRNA]; sodium propionate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA] |
CTD |
PMID:31621310 |
|
NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902
|
|
G |
HDAC2 |
histone deacetylase 2 |
multiple interactions |
ISO |
sodium propionate inhibits the reaction [Ethanol results in increased expression of HDAC2 mRNA]; sodium propionate inhibits the reaction [Ethanol results in increased expression of HDAC2 protein] |
CTD |
PMID:35639301 |
|
NCBI chr 6:113,933,028...113,971,148
Ensembl chr 6:113,933,028...114,011,308
|
|
G |
HDAC6 |
histone deacetylase 6 |
multiple interactions |
ISO |
sodium propionate inhibits the reaction [Ethanol results in increased expression of HDAC6 mRNA] |
CTD |
PMID:35639301 |
|
NCBI chr X:48,801,398...48,824,982
Ensembl chr X:48,801,377...48,824,982
|
|
G |
IFNG |
interferon gamma |
multiple interactions |
ISO |
[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IFNG mRNA] |
CTD |
PMID:37269894 |
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
IKBKB |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
ISO |
[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IKBKB mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IKBKB protein] |
CTD |
PMID:37269894 |
|
NCBI chr 8:42,271,302...42,332,460
Ensembl chr 8:42,271,302...42,332,460
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
ISO |
[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IL6 mRNA] |
CTD |
PMID:37269894 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
MT1A |
metallothionein 1A |
multiple interactions increases expression |
ISO |
[sodium propionate co-treated with Cadmium] results in increased expression of MT1A mRNA; [sodium propionate co-treated with Dexamethasone] results in increased expression of MT1A mRNA sodium propionate results in increased expression of MT1A mRNA |
CTD |
PMID:1597404 |
|
NCBI chr16:56,638,666...56,640,087
Ensembl chr16:56,638,666...56,640,087
|
|
G |
MYD88 |
MYD88 innate immune signal transduction adaptor |
multiple interactions |
ISO |
[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of MYD88 mRNA] |
CTD |
PMID:37269894 |
|
NCBI chr 3:38,138,661...38,143,022
Ensembl chr 3:38,138,552...38,143,024
|
|
G |
NFKBIA |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in decreased expression of NFKBIA protein] |
CTD |
PMID:37269894 |
|
NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
sodium propionate inhibits the reaction [Ethanol results in increased expression of NOS2 mRNA] |
CTD |
PMID:35639301 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NOX1 |
NADPH oxidase 1 |
multiple interactions |
ISO |
sodium propionate inhibits the reaction [Ethanol results in increased expression of NOX1 mRNA]; sodium propionate inhibits the reaction [TNF protein affects the acetylation of NOX1 promoter] |
CTD |
PMID:35639301 |
|
NCBI chr X:100,843,324...100,874,359
Ensembl chr X:100,843,324...100,874,359
|
|
G |
OCLN |
occludin |
multiple interactions |
ISO |
sodium propionate inhibits the reaction [Ethanol results in decreased expression of OCLN protein] |
CTD |
PMID:35639301 |
|
NCBI chr 5:69,492,547...69,558,104
Ensembl chr 5:69,492,292...69,558,104
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of and results in increased phosphorylation of RELA protein]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of RELA mRNA] |
CTD |
PMID:37269894 |
|
NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
multiple interactions |
ISO |
[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TGFB1 mRNA] |
CTD |
PMID:37269894 |
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
TJP1 |
tight junction protein 1 |
multiple interactions |
ISO |
sodium propionate inhibits the reaction [Ethanol results in decreased expression of TJP1 protein] |
CTD |
PMID:35639301 |
|
NCBI chr15:29,699,367...29,969,049
Ensembl chr15:29,699,367...29,968,915
|
|
G |
TLR2 |
toll like receptor 2 |
multiple interactions |
ISO |
[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR2 mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR2 protein] |
CTD |
PMID:37269894 |
|
NCBI chr 4:153,684,280...153,710,637
Ensembl chr 4:153,684,070...153,706,260
|
|
G |
TLR4 |
toll like receptor 4 |
multiple interactions |
ISO |
[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR4 mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR4 protein] |
CTD |
PMID:37269894 |
|
NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
ISO |
[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TNF mRNA]; sodium propionate inhibits the reaction [TNF protein affects the acetylation of NOX1 promoter] |
CTD |
PMID:35639301 PMID:37269894 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
UGT1A1 |
UDP glucuronosyltransferase family 1 member A1 |
multiple interactions |
EXP |
sodium propionate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of UGT1A1 mRNA] |
CTD |
PMID:31621310 |
|
NCBI chr 2:233,760,270...233,773,300
Ensembl chr 2:233,760,270...233,773,300
|
|